Home / Business and Economy / Sino Biopharma partners with AstraZeneca for global drug rights
Sino Biopharma partners with AstraZeneca for global drug rights
8 Jul
Summary
- Sino Biopharmaceutical granted global rights for a respiratory drug.
- The deal includes potential payments up to $1.9 billion.
- AstraZeneca will develop the drug outside of China.
Sino Biopharmaceutical has entered into a significant agreement with AstraZeneca. The Hong Kong-listed company has granted AstraZeneca the rights to develop a drug targeting chronic respiratory diseases. This groundbreaking collaboration extends beyond China's borders.
AstraZeneca will be responsible for the further development of this promising therapeutic in markets worldwide. The financial terms of the deal are substantial, with Sino Biopharmaceutical potentially receiving up to $1.9 billion in total payments as part of this arrangement.
This partnership signifies a major step for Sino Biopharmaceutical's efforts to commercialize its respiratory drug on a global scale. AstraZeneca's involvement is expected to accelerate the drug's path through international development and regulatory processes.
